

Atty. Docket No. PZ003P4

page 81, lines 8-31; page 124 through 125; and, page 135, lines 1-3. Accordingly, in view of the above explanation, Applicants respectfully request that the rejection be withdrawn.

Remarks

Applicants have herein amended claims 24, 28, 34, 39, 44, 49, 54, 59, 64, 69, and 74. Applicants have otherwise addressed all of the issues and rejections asserted in the presently pending Office Action. Applicants submit that all rejections have been accommodated, obviated, overcome, or rendered moot. Accordingly, Applicants request that the rejection of pending claims 24-75 be reconsidered and withdrawn.

Atty. Docket No. PZ003P4


Conclusion

Applicants respectfully request that the above-made amendment and remarks be entered and made of record in the file history of the instant application. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicant would expedite the examination of this application.

If there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an extension is requested and the fee should also be charged to our Deposit Account.


Respectfully submitted,

Date: SEPTEMBER 4, 2002


Janet M. Martineau (Reg. No. 46,903)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 315-2723 (phone)

KKH/JMM/DS

Telecopier Transmission Certificate	
Send date: September 4, 2002	
I hereby certify that this paper and the attachments hereto are being sent by telecopier transmission to 703-9306 on the above-indicated date addressed to:	
872	Examiner S. Pappu - Group 1636 U.S. Patent and Trademark Office Washington, D.C. 20231
 Janet M. Martineau Date	

In re Patent Application of:

Docket No.: PZ003P4

Ruben, et al.

Application No.: 09/852,659

Group Art Unit: 1636

Filed: May 11, 2001

Examiner: S. Pappu

For: 28 Human Secreted Proteins**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

(underline = text inserted; strike-through = text deleted)

Please amend claims 24, 28, 34, 39, 44, 49, 54, 59, 64, 69, and 74, as follows:

24. (Once Amended) An isolated protein comprising the sequence set forth in SEQ ID NO:85 from residues 19 to 121 amino-acid residues 19 to 121 of SEQ ID NO:85.

28. (Once Amended) A composition comprising the protein of claim 24 and a pharmaceutically an acceptable carrier.

34. (Once Amended) A composition comprising the protein of claim 30 and a pharmaceutically an acceptable carrier.

39. (Once Amended) A composition comprising the protein of claim 36 and a pharmaceutically an acceptable carrier.

44. (Once Amended) A composition comprising the protein of claim 41 and a pharmaceutically an acceptable carrier.

49. (Once Amended) A composition comprising the protein of claim 46 and a pharmaceutically an acceptable carrier.

54. (Once Amended) A composition comprising the protein of claim 51 and a pharmaceutically an acceptable carrier.

59. (Once Amended) A composition comprising the protein of claim 56 and a pharmaceutically an acceptable carrier.

64. (Once Amended) A composition comprising the protein of claim 61 and pharmaceutically an acceptable carrier.

69. (Once Amended) A composition comprising the protein of claim 66 and a pharmaceutically an acceptable carrier.

74. (Once Amended) A composition comprising the protein of claim 71 and pharmaceutically an acceptable carrier.